BlueRock Therapeutics
BlueRock Therapeutics is a pioneering cell therapy company dedicated to transforming the treatment of degenerative diseases through innovative regenerative medicines. Founded in 2016 and now a wholly owned subsidiary of Bayer AG, it focuses on developing authentic cell therapies for neurological, ophthalmic, cardiovascular, and immunological diseases, leveraging its proprietary _CELL+GENE_ platform and advanced cell differentiation technology. The company is committed to scientific innovation, integrity, community, and acting with urgency to deliver hope and improve patient lives.
Industries
Nr. of Employees
large (251-1000)
BlueRock Therapeutics
Products
Pluripotent stem cell–derived dopaminergic neuron therapy (clinical program)
A pluripotent stem cell–derived dopaminergic neuron precursor therapy evaluated via surgical implantation for treatment of Parkinson’s disease; clinical program includes Phase I safety/tolerability data and progression toward a randomized registrational Phase III trial.
Pluripotent stem cell–derived photoreceptor therapy (clinical program)
An iPSC-derived photoreceptor replacement therapy candidate with IND clearance to initiate Phase 1/2a clinical testing for primary photoreceptor diseases, supported by external IND-enabling manufacturing partnerships.
Preclinical cardiac remuscularization programs
Preclinical programs developing pluripotent stem cell–derived cardiomyocytes and related engineered cell products aimed at remuscularization of injured myocardium.
Pluripotent stem cell–derived dopaminergic neuron therapy (clinical program)
A pluripotent stem cell–derived dopaminergic neuron precursor therapy evaluated via surgical implantation for treatment of Parkinson’s disease; clinical program includes Phase I safety/tolerability data and progression toward a randomized registrational Phase III trial.
Pluripotent stem cell–derived photoreceptor therapy (clinical program)
An iPSC-derived photoreceptor replacement therapy candidate with IND clearance to initiate Phase 1/2a clinical testing for primary photoreceptor diseases, supported by external IND-enabling manufacturing partnerships.
Preclinical cardiac remuscularization programs
Preclinical programs developing pluripotent stem cell–derived cardiomyocytes and related engineered cell products aimed at remuscularization of injured myocardium.
Services
Research collaboration for natural history and outcome measure development
Collaborative studies with patient-focused natural history consortia to generate data used to inform clinical trial endpoint selection and sensitivity for inherited retinal and other diseases.
Discovery and manufacturing collaboration for iPSC-derived regulatory T cells
Joint discovery program leveraging an external discovery platform to identify reprogramming factor combinations for manufacturing regulatory T cells, with options for licensing precision programming methods.
Clinical trial design and registrational trial execution support
Design and operational support for multi-site clinical programs, including randomized, sham-controlled registrational trials and long-term follow-up studies for surgical cell transplantation programs.
External manufacturing and cGMP partnership facilitation
Coordination and management of relationships with external cGMP manufacturers to support clinical manufacturing, IND-enabling studies and technology transfer.
Research collaboration for natural history and outcome measure development
Collaborative studies with patient-focused natural history consortia to generate data used to inform clinical trial endpoint selection and sensitivity for inherited retinal and other diseases.
Discovery and manufacturing collaboration for iPSC-derived regulatory T cells
Joint discovery program leveraging an external discovery platform to identify reprogramming factor combinations for manufacturing regulatory T cells, with options for licensing precision programming methods.
Clinical trial design and registrational trial execution support
Design and operational support for multi-site clinical programs, including randomized, sham-controlled registrational trials and long-term follow-up studies for surgical cell transplantation programs.
External manufacturing and cGMP partnership facilitation
Coordination and management of relationships with external cGMP manufacturers to support clinical manufacturing, IND-enabling studies and technology transfer.
Expertise Areas
- iPSC-based cell therapy development
- Directed differentiation and neuronal lineage derivation
- Transcription factor–based cell programming and ML-assisted discovery
- Genome editing for donor-compatible allogeneic cell lines
Key Technologies
- Induced pluripotent stem cells (iPSC)
- Human pluripotent stem cell–derived neuronal precursors
- Directed differentiation protocols (developmental signaling modulation, e.g., WNT)
- Transcription factor–mediated reprogramming